BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31851045)

  • 1. Molecular characterization of endometrial cancer and therapeutic implications.
    Winterhoff B; Thomaier L; Mullany S; Powell MA
    Curr Opin Obstet Gynecol; 2020 Feb; 32(1):76-83. PubMed ID: 31851045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of endometrial cancer and therapeutic implications.
    Chang Z; Talukdar S; Mullany SA; Winterhoff B
    Curr Opin Obstet Gynecol; 2019 Feb; 31(1):24-30. PubMed ID: 30507624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
    Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
    Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization of endometrial cancer and therapeutic implications.
    Uppendahl L; Mullany SA; Winterhoff B
    Curr Opin Obstet Gynecol; 2017 Feb; 29(1):35-39. PubMed ID: 27941362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy.
    Prendergast EN; Holman LL; Liu AY; Lai TS; Campos MP; Fahey JN; Wang X; Abdelaal N; Rao JY; Elvin JA; Moore KM; Konecny GE; Cohen JG
    Gynecol Oncol; 2019 Sep; 154(3):461-466. PubMed ID: 31257009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Genetics of Endometrial Carcinoma.
    Bell DW; Ellenson LH
    Annu Rev Pathol; 2019 Jan; 14():339-367. PubMed ID: 30332563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
    Moroney MR; Davies KD; Wilberger AC; Sheeder J; Post MD; Berning AA; Fisher C; Lefkowits C; Guntupalli SR; Behbakht K; Corr BR
    Gynecol Oncol; 2019 Jun; 153(3):517-520. PubMed ID: 30910249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas.
    Wang M; Hui P
    Arch Pathol Lab Med; 2021 Nov; 145(11):1367-1378. PubMed ID: 34673912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of Endometrial Carcinoma: New Perspectives Beyond Morphology.
    Akhtar M; Al Hyassat S; Elaiwy O; Rashid S; Al-Nabet ADMH
    Adv Anat Pathol; 2019 Nov; 26(6):421-427. PubMed ID: 31567131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging genomic landscape of endometrial cancer.
    Le Gallo M; Bell DW
    Clin Chem; 2014 Jan; 60(1):98-110. PubMed ID: 24170611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of
    Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
    Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment options for molecular subtypes of endometrial cancer in 2023.
    Karpel HC; Slomovitz B; Coleman RL; Pothuri B
    Curr Opin Obstet Gynecol; 2023 Jun; 35(3):270-278. PubMed ID: 36943683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
    Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
    Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
    Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
    Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Endometrial carcinomas in 2021: What to say and what to do?].
    Just PA; Genestie C
    Ann Pathol; 2022 Mar; 42(2):104-112. PubMed ID: 34340872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reclassifying endometrial carcinomas with a combined morphological and molecular approach.
    Carlson J; McCluggage WG
    Curr Opin Oncol; 2019 Sep; 31(5):411-419. PubMed ID: 31261170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies.
    Yang Y; Wu SF; Bao W
    Int J Gynaecol Obstet; 2024 Feb; 164(2):436-459. PubMed ID: 37525501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current prerequisites for a molecular genetic classification of endometrial cancer].
    Vtorushin SV; Malykh RD
    Arkh Patol; 2017; 79(3):57-62. PubMed ID: 28631718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma.
    Travaglino A; Raffone A; Gencarelli A; Mollo A; Guida M; Insabato L; Santoro A; Zannoni GF; Zullo F
    Pathol Oncol Res; 2020 Oct; 26(4):2067-2073. PubMed ID: 32472441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker-driven therapy in endometrial cancer.
    Karpel H; Slomovitz B; Coleman RL; Pothuri B
    Int J Gynecol Cancer; 2023 Mar; 33(3):343-350. PubMed ID: 36878569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.